Slone Partners Recruits Chief Scientific Officer for Enveda Biosciences | Hunt Scanlon Media

April 30, 2021 – Over the previous few months, quite a few healthcare and life sciences organizations have turned to govt search companies to search out new leaders. In the period of COVID-19, the sector has been a burgeoning space for govt search companies to ply their commerce. Recently, life sciences-focused search agency Slone Partners positioned Sotirios Karathanasis as the brand new chief science officer at Enveda Biosciences. “Dr. Karathanasis is a highly accomplished and respected scientist, researcher and innovator with broad drug discovery and development experience whose intellect and insights will advance Enveda’s impressive drug discovery portfolio,” mentioned Tara Kochis-Stach, president of Slone Partners. “He will make a terrific addition to the company’s executive leadership team.”

“Sotirios will bring critical expertise and proven executive leadership to our mission of developing a world-class portfolio in cardiovascular, metabolic and other complex diseases that have proven refractory to conventional methods,” mentioned Viswa Colluru, founder and CEO of Enveda. “His experience will help our team of biologists and medicinal chemists deliver validated, first-in-class drug candidates inspired by unique chemical starting points.”

Dr. Karathanasis is former chief science officer of endocrine and cardiovascular analysis at Lilly Research Laboratories and has held a number of different key positions within the pharmaceutical business together with vice chairman and head of biosciences at AstraZeneca, and director of cardiovascular pharmacology at Pfizer Global Research & Development. Over the course of his profession, Dr. Karathanasis has led drug discovery groups with as many as 250 scientists throughout a large scope of geographic places, disciplines and practical interfaces. He holds 23 patents and has revealed greater than 100 authentic manuscripts, evaluation papers, and e-book chapters. Dr. Karathanasis acquired his doctorate in biochemistry on the University of Georgia and served his post-doctoral fellowship at Harvard Medical School.

In his new position, Dr. Karathanasis will lead the corporate’s small molecule drug discovery portfolio and work with Enveda’s preclinical staff to advance the corporate’s lead packages for NASH and Wilson’s illness, amongst different packages.

“Having generated the largest dataset of medicinally-important plant metabolomes purpose-built for machine learning, Enveda is unlocking a new era of small molecule discovery,” mentioned Dr. Karathanasis. “I see tremendous potential in Enveda’s technology to address challenging targets and fundamental disease-causing processes.”

Related: Slone Partners Recruits Chief Business Officer for InterVenn Biosciences

Enveda Biosciences is a biotechnology firm constructing the primary high-resolution chemical map of the pure world to deal with the hardest issues in drug discovery. Enveda’s platform is a complicated drug discovery search engine for darkish chemical house, constructing on years developments on the intersection of metabolomics and machine studying. Complementing its breakthrough expertise, Enveda’s staff contains seasoned drug hunters with many years of expertise within the pharmaceutical business working alongside world-leading knowledge scientists.

Nationally Recognized

Slone Partners is a nationally acknowledged senior-level recruitment supplier that focuses on delivering govt, administration and management expertise for the diagnostic, biopharmaceutical, healthcare data expertise and laboratory testing industries. The agency has workplaces in Boston, New York, Washington, D.C. and San Francisco. Recently, the agency was included amongst Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”


Slone Partners Recruits CEO for Mesa Biotech
The race is on to discover a vaccine for COVID-19 – and together with it the tempo is selecting as much as discover prime management expertise at lots of the nation’s main life sciences, medical diagnostics and biotech firms. Here’s one of many newest searches simply efficiently accomplished.


Ms. Kochis-Stach joined Slone Partners in 2004, bringing to the agency over a decade of healthcare expertise. Her previous gross sales profession with business leaders corresponding to VERSYSS, American Medical Laboratories and Quest Diagnostics lined all kinds of healthcare segments, together with data expertise, medical information, and the diagnostic and laboratory testing business. Prior to healthcare, Ms. Kochis-Stach recruited govt and administration expertise within the banking and finance sector.

Recent Placement

The firm recently placed Mike Spigarelli as chief medical officer of Lumen Bioscience in Seattle. “As an extremely skilled industry leader with three decades of medical, pharmaceutical and academic experience, Mike Spigarelli has a thorough understanding of clinical affairs, drug development and regulatory strategy,” mentioned Ms. Kochis-Stach, of Slone Partners. “He will be a tremendously valuable addition to the Lumen Bio executive team at a time when the company is advancing a number of exciting new investigational biologic drugs.”

Related: Slone Partners Places Chief Medical Officer at Goldfinch Bio

Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media

LEAVE A REPLY

Please enter your comment!
Please enter your name here